naltrexone and topiramate

naltrexone has been researched along with topiramate in 77 studies

Research

Studies (77)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	21 (27.27)	29.6817
2010's	47 (61.04)	24.3611
2020's	9 (11.69)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Ekins, S; Williams, AJ; Xu, JJ	1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Salaspuro, M	1
Anton, R; Myrick, H	1
Kenna, GA; McGeary, JE; Swift, RM	1
Egli, M; Heilig, M	1
Pettinati, HM; Rabinowitz, AR	1
Roesner, S; Soyka, M	1
Johnson, BA	2
Dannon, PN; Gonopolsky, Y; Kotler, M; Lowengrub, K; Musin, E	1
Kuehn, BM	1
Berglund, M; Gorelick, D; Hesselbrock, V; Johnson, BA; Kranzler, HR; Möller, HJ; Soyka, M	1
Alvarez, S; Bobes, J; Flórez, G; García-Portilla, P; Nogueiras, L; Saiz, PA	3
Baltieri, DA; Daró, FR; de Andrade, AG; Ribeiro, PL	2
Garbutt, JC	1
Andrade, AG; Baltieri, DA; Daró, FR; Ribeiro, PL	1
Basu, D; Shah, R	1
de Silva, V; Hanwella, R	1
Falk, D; Fertig, J; Johnson, B; Litten, RZ; Liu, L; Mattson, M; Ryan, M; Stout, R; Wang, XQ	1
Bray, GA; Ryan, DH	1
Goldfine, AB; Hiatt, WR; Thomas, A	1
Book, SW; Miller, PM; Stewart, SH	1
Chen, J; Isaac, M; Johnson, BA; Liu, L; O'Quigley, J; Wang, XQ; Zhang, D	1
Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J	1
Manzanares, J; Navarrete, F; Rubio, G	1
O'Connor, PG; O'Malley, SS	1
Gillman, AG; Kosobud, AE; Leffel, JK; Timberlake, W	1
Aubin, HJ; Daeppen, JB	1
Johnson, BA; Lynch, WJ; Moore, CF; Protzuk, OA	1
Heinz, A; Müller, CA	1
Anton, RF; Falk, DE; Johnson, BA; Kranzler, HR; Litten, RZ	1
Nakazato, M; Ueno, H	1
Amick, HR; Bobashev, G; Feltner, C; Garbutt, JC; Gass, CE; Jonas, DE; Kim, MM; Rowe, CJ; Shanahan, E; Thomas, K; Wines, R	1
Liang, J; Olsen, RW	1
Aldhoon-Hainerová, I; Hainer, V	1
Hainer, V	1
Cunningham, JW; Wiviott, SD	1
Goutier, W; Kloeze, M; McCreary, AC	1
Citrome, L	1
Rubio, MA	1
Dahiya, N; Kakkar, AK	1
Fujioka, K	1
Bragg, R; Crannage, E	1
Helton, SG; Lohoff, FW	1
Megyeri, J; Nuffer, W; Trujillo, JM	1
Camilleri, M; Chandar, AK; Dulai, PS; Khera, R; Loomba, R; Murad, MH; Prokop, LJ; Singh, S; Wang, Z	1
Bowe, T; Christopher, M; Finlay, AK; Gidwani, R; Hagedorn, H; Harris, AH; Kay, C; Nevedal, A; Rosen, C	1
Halpern, B; Mancini, MC	1
Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH	1
Goh, ET; Morgan, MY	1
Lyon, J	1
Boussageon, R; Duprez, R; Huneau, A; Laviolle, B; Locher, C; Naudet, F; Palpacuer, C	1
Donoghue, K	1
Baillie, A; Haber, PS; Kranzler, HR; Luquin, N; Morley, KC; Shanahan, M; Teesson, M; Trent, R	1
Barrea, L; Cataldi, M; Colao, A; Guida, B; Muscogiuri, G; Savastano, S; Taglialatela, M	1
Harris, AHS; Matson, TE; Williams, EC	1
Anton, RF; Falk, DE; Fertig, J; Hasin, DS; Johnson, B; Kranzler, HR; Litten, RZ; Mann, KF; Meulien, D; O'Malley, SS; Ryan, M; Slater, M; Witkiewitz, K	1
Brown, SA; Izzy, M; Watt, KD	1
Lee, SY; Tak, YJ	1
Berghold, A; Horvath, K; Jeitler, K; Krenn, C; Semlitsch, T; Siebenhofer, A; Winterholer, S	1
Ahamad, K; Bach, P; Mong, J	1
Burnette, EM; Gillis, AJ; Grodin, EN; Hurley, B; Meredith, LR; Miotto, K; Nieto, SJ; Ray, LA	1
Fomin, V; Goodman, RP; Luther, J; Patel, SJ; Schaefer, E; Shay, JES; Vannier, AGL	1
Correa, OMT; Doretto-Silva, L; Morreale, S; Nassis, C; Petri, G; Santos, JFRD; Scudeler, MA; Veridiano, JM	1
Hill, A; Levi, J; Venter, F; Wang, J	1
Alto, M; Giusto, A; Greene, MC; Johnson, RM; Kane, J; Lovero, K; McClendon, J; Nicholson, T; Stockton, M; Tol, WA; Wainberg, ML	1

Reviews

38 review(s) available for naltrexone and topiramate

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
[Drug therapy of alcohol dependence--a critical review]. Duodecim; laaketieteellinen aikakauskirja, 2003, Volume: 119, Issue:24 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Fructose; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Topiramate	2003
Recent advances in the pharmacotherapy of alcoholism. Current psychiatry reports, 2004, Volume: 6, Issue:5 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Clinical Trials as Topic; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neurotransmitter Agents; Taurine; Topiramate	2004
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Nov-15, Volume: 61, Issue:22 Topics: Alcohol Deterrents; Alcoholism; Aripiprazole; Behavior Therapy; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Pharmacogenetics; Piperazines; Quinolones; Topiramate	2004
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacology & therapeutics, 2006, Volume: 111, Issue:3 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Neuropeptide Y; Nociceptin; Ondansetron; Opioid Peptides; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Taurine; Topiramate	2006
Choosing the right medication for the treatment of alcoholism. Current psychiatry reports, 2006, Volume: 8, Issue:5 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Choice Behavior; Cognitive Behavioral Therapy; Combined Modality Therapy; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Taurine; Topiramate	2006
New pharmacological approaches for the treatment of alcoholism. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:17 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Secondary Prevention; Taurine; Topiramate	2006
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochemical pharmacology, 2008, Jan-01, Volume: 75, Issue:1 Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Receptors, N-Methyl-D-Aspartate; Ritanserin; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate	2008
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2008, Volume: 9, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biological Psychiatry; Carbamazepine; Disulfiram; Fructose; Health Planning Guidelines; Humans; Naltrexone; Ondansetron; Societies, Scientific; Substance-Related Disorders; Taurine; Topiramate	2008
The state of pharmacotherapy for the treatment of alcohol dependence. Journal of substance abuse treatment, 2009, Volume: 36, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations; Disulfiram; Fructose; Humans; Medication Adherence; Naltrexone; Taurine; Temperance; Topiramate	2009
Medication treatment of different types of alcoholism. The American journal of psychiatry, 2010, Volume: 167, Issue:6 Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Chronic Disease; Depressive Disorder; Female; Fructose; Humans; Hypothalamo-Hypophyseal System; Limbic System; Male; Naltrexone; Ondansetron; Pituitary-Adrenal System; Prefrontal Cortex; Receptors, Dopamine D2; Receptors, GABA; Topiramate; Young Adult	2010
Medical treatment of alcohol dependence: a systematic review. International journal of psychiatry in medicine, 2011, Volume: 42, Issue:3 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Antagonists; Off-Label Use; Taurine; Topiramate; Treatment Outcome	2011
Recent advancements in drug treatment of obesity. Clinical medicine (London, England), 2012, Volume: 12, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss	2012
Medications for unhealthy alcohol use: across the spectrum. Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism, 2011, Volume: 33, Issue:4 Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Disulfiram; Dopamine Agents; Fructose; Humans; Naltrexone; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate	2011
Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption. Drug and alcohol dependence, 2013, Nov-01, Volume: 133, Issue:1 Topics: Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Aripiprazole; Flupenthixol; Fluvoxamine; Fructose; Humans; Naltrexone; Piperazines; Psychotropic Drugs; Quinolones; Topiramate	2013
[New treatment options for alcohol dependence]. MMW Fortschritte der Medizin, 2013, May-02, Volume: 155, Issue:8 Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; Psychotherapy; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Topiramate	2013
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3 Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate	2014
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA, 2014, May-14, Volume: 311, Issue:18 Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; Randomized Controlled Trials as Topic; Taurine; Topiramate	2014
Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors. Acta pharmacologica Sinica, 2014, Volume: 35, Issue:8 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Benzodiazepines; Disulfiram; Ethanol; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Plant Preparations; Receptors, GABA-A; Taurine; Topiramate	2014
Tolerability and safety of the new anti-obesity medications. Drug safety, 2014, Volume: 37, Issue:9 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate	2014
Overview of new antiobesity drugs. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2014
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. Clinical cardiology, 2014, Volume: 37, Issue:11 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Fructose; Heart; Humans; Naltrexone; Obesity; Phentermine; Topiramate	2014
Drug treatment of obesity: current status and future prospects. European journal of internal medicine, 2015, Volume: 26, Issue:2 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Drug Combinations; Drug Therapy, Combination; Fructose; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate	2015
Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring, Md.), 2015, Volume: 23 Suppl 1 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss	2015
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. Psychiatry research, 2015, Dec-15, Volume: 230, Issue:2 Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Disulfiram; Fructose; Humans; Naltrexone; Pharmacogenetics; Precision Medicine; Taurine; Topiramate; United States	2015
A Comparison of New Pharmacological Agents for the Treatment of Obesity. The Annals of pharmacotherapy, 2016, Volume: 50, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2016
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 2016, Jun-14, Volume: 315, Issue:22 Topics: Anti-Obesity Agents; Bayes Theorem; Benzazepines; Drug Combinations; Female; Fructose; Humans; Lactones; Liraglutide; Male; Middle Aged; Naltrexone; Obesity; Orlistat; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Weight Loss	2016
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Expert opinion on drug safety, 2017, Volume: 16, Issue:1 Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate	2017
Practical Use of Pharmacotherapy for Obesity. Gastroenterology, 2017, Volume: 152, Issue:7 Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain	2017
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:7 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Humans; Naltrexone; Polymorphism, Single Nucleotide; Pyridoxine; Pyrrolidonecarboxylic Acid; Taurine; Topiramate; Treatment Outcome	2017
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction (Abingdon, England), 2018, Volume: 113, Issue:2 Topics: Acamprosate; Alcoholism; Baclofen; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate; Treatment Outcome	2018
Gender-related issues in the pharmacology of new anti-obesity drugs. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2019, Volume: 20, Issue:3 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Liraglutide; Male; Naltrexone; Obesity; Patient Selection; Sex Factors; Topiramate; Treatment Outcome; Weight Loss	2019
Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions. Addiction science & clinical practice, 2019, 02-12, Volume: 14, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Clinical Trials as Topic; Disulfiram; Naltrexone; Practice Patterns, Physicians'; Topiramate; United States; United States Department of Veterans Affairs; Veterans	2019
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential. Hepatology (Baltimore, Md.), 2021, Volume: 73, Issue:5 Topics: Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Humans; Liraglutide; Liver Cirrhosis; Liver Transplantation; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Translational Science, Biomedical	2021
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Current obesity reports, 2021, Volume: 10, Issue:1 Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss	2021
Long-term effects of weight-reducing drugs in people with hypertension. The Cochrane database of systematic reviews, 2021, 01-17, Volume: 1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Bias; Blood Pressure; Body Weight; Bupropion; Diet, Reducing; Drug Combinations; Female; Fructose; Humans; Hypertension; Lactones; Male; Middle Aged; Naltrexone; Orlistat; Phentermine; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Time; Topiramate	2021
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. Drugs, 2022, Volume: 82, Issue:3 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Humans; Naltrexone; Topiramate	2022
Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries. The Cochrane database of systematic reviews, 2023, 05-09, Volume: 5 Topics: Acamprosate; Alcoholism; Amitriptyline; Developing Countries; Disulfiram; Humans; Male; Mirtazapine; Naltrexone; Ondansetron; Topiramate	2023

Trials

9 trial(s) available for naltrexone and topiramate

Article	Year
Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcoholism, clinical and experimental research, 2008, Volume: 32, Issue:7 Topics: Adult; Alcoholism; Female; Fructose; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Psychological Tests; Severity of Illness Index; Topiramate	2008
Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction (Abingdon, England), 2008, Volume: 103, Issue:12 Topics: Adolescent; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Fructose; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Socioeconomic Factors; Topiramate; Treatment Outcome; Young Adult	2008
The role of alcoholic beverage preference in the severity of alcohol dependence and adherence to the treatment. Alcohol (Fayetteville, N.Y.), 2009, Volume: 43, Issue:3 Topics: Adolescent; Adult; Alcoholic Beverages; Alcoholism; Beer; Fructose; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Patient Compliance; Topiramate; Treatment Outcome	2009
Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug and alcohol dependence, 2009, Nov-01, Volume: 105, Issue:1-2 Topics: Adolescent; Adult; Alcoholism; Analysis of Variance; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fructose; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outpatients; Patient Compliance; Secondary Prevention; Smoking; Smoking Cessation; Socioeconomic Factors; Topiramate; Treatment Outcome; Young Adult	2009
Topiramate for the treatment of alcohol dependence: comparison with naltrexone. European addiction research, 2011, Volume: 17, Issue:1 Topics: Alcohol Drinking; Alcoholism; Excitatory Amino Acid Agents; Female; Fructose; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Quality of Life; Time Factors; Topiramate; Treatment Outcome	2011
Trajectory analyses in alcohol treatment research. Alcoholism, clinical and experimental research, 2012, Volume: 36, Issue:8 Topics: Acamprosate; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Algorithms; Behavior Therapy; Combined Modality Therapy; Data Interpretation, Statistical; Double-Blind Method; Female; Fructose; Humans; Linear Models; Male; Middle Aged; Models, Statistical; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Nonlinear Dynamics; Regression Analysis; Research; Research Design; Taurine; Topiramate; Treatment Outcome; Young Adult	2012
Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials. Journal of studies on alcohol and drugs, 2014, Volume: 75, Issue:2 Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Double-Blind Method; Fructose; Humans; Naltrexone; Narcotic Antagonists; Topiramate; Treatment Outcome	2014
Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). Trials, 2018, Aug-16, Volume: 19, Issue:1 Topics: Adolescent; Adult; Aged; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Clinical Protocols; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Gene Frequency; Homozygote; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; New South Wales; Pharmacogenomic Variants; Prospective Studies; Receptors, Kainic Acid; Receptors, Opioid, mu; Recurrence; Research Design; Time Factors; Topiramate; Treatment Outcome; Young Adult	2018
Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA psychiatry, 2019, 04-01, Volume: 76, Issue:4 Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Risk Assessment; Topiramate; Varenicline	2019

Other Studies

30 other study(ies) available for naltrexone and topiramate

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24 Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility	2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Drug treatment for alcoholism today. The Harvard mental health letter, 2005, Volume: 22, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Disulfiram; Fructose; Humans; Naltrexone; Substance Withdrawal Syndrome; Taurine; Topiramate	2005
12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:6 Topics: Adolescent; Adult; Analysis of Variance; Bupropion; Delayed-Action Preparations; Drug Therapy; Fluvoxamine; Follow-Up Studies; Fructose; Gambling; Humans; Israel; Male; Middle Aged; Naltrexone; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Psychopharmacology; Recurrence; Reproducibility of Results; Surveys and Questionnaires; Time Factors; Topiramate	2007
New therapies for alcohol dependence open options for office-based treatment. JAMA, 2007, Dec-05, Volume: 298, Issue:21 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family Practice; Fructose; Humans; Naltrexone; Taurine; Topiramate	2007
Topiramate: 'small is beautiful'? Addiction (Abingdon, England), 2009, Volume: 104, Issue:8 Topics: Alcohol Deterrents; Alcohol-Related Disorders; Fructose; Humans; Naltrexone; Topiramate; Treatment Outcome	2009
Treatment of alcohol dependence. The Ceylon medical journal, 2009, Volume: 54, Issue:2 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Taurine; Topiramate; Vitamins	2009
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support. Prescrire international, 2009, Volume: 18, Issue:103 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism; Anticonvulsants; Baclofen; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; France; Fructose; Health Status; Humans; Naltrexone; Psychotherapy; Randomized Controlled Trials as Topic; Secondary Prevention; Self-Help Groups; Social Support; Taurine; Temperance; Topiramate; Treatment Outcome	2009
Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcoholism, clinical and experimental research, 2010, Volume: 34, Issue:12 Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Fructose; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Taurine; Temperance; Time Factors; Topiramate; Treatment Outcome	2010
[Amisulpride for the treatment of alcohol dependence]. Adicciones, 2011, Volume: 23, Issue:2 Topics: Alcoholism; Amisulpride; Anticonvulsants; Antipsychotic Agents; Female; Fructose; Humans; Male; Naltrexone; Narcotic Antagonists; Sulpiride; Topiramate	2011
Drug treatment of obesity. The Psychiatric clinics of North America, 2011, Volume: 34, Issue:4 Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupropion; Child; Drug Approval; Drug Combinations; Energy Intake; Exenatide; Female; Fructose; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lactones; Male; Metformin; Naltrexone; Narcotic Antagonists; Obesity; Orlistat; Patient Compliance; Peptides; Randomized Controlled Trials as Topic; Sympathomimetics; Topiramate; United States; United States Food and Drug Administration; Venoms	2011
What cost weight loss? Circulation, 2012, Mar-06, Volume: 125, Issue:9 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; Phentermine; Risk Assessment; Risk Factors; Topiramate; Weight Loss	2012
Effects of naltrexone plus topiramate on ethanol self-administration and tyrosine hydroxylase gene expression changes. Addiction biology, 2014, Volume: 19, Issue:5 Topics: Administration, Oral; Alcohol Drinking; Analysis of Variance; Animals; Central Nervous System Agents; Central Nervous System Depressants; Conditioning, Operant; Drug Combinations; Ethanol; Fructose; Gene Expression; Mice, Inbred C57BL; Motivation; Naltrexone; Self Administration; Topiramate; Tyrosine 3-Monooxygenase; Ventral Tegmental Area	2014
Behavioral characteristics and pharmacological manipulations of a nicotine-entrainable circadian oscillator. Chronobiology international, 2013, Volume: 30, Issue:7 Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Behavior, Animal; Benzoxazoles; Circadian Rhythm; Feeding Behavior; Female; Fructose; Light; Motor Activity; Naltrexone; Naphthyridines; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Oscillometry; Rats; Rats, Sprague-Dawley; Time Factors; Topiramate; Urea	2013
The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models. Pharmacology, biochemistry, and behavior, 2014, Volume: 116 Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Drug Combinations; Ethanol; Fructose; Models, Animal; Naltrexone; Rats; Rats, Wistar; Topiramate	2014
Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids. Addiction biology, 2016, Volume: 21, Issue:2 Topics: Acamprosate; Analysis of Variance; Animals; Antidiuretic Hormone Receptor Antagonists; Bupropion; Dose-Response Relationship, Drug; Fructose; Indoles; Male; Motor Activity; Naltrexone; Nicotine; Nicotinic Agonists; Pyrrolidines; Rats, Wistar; Taurine; Tobacco Use Cessation Devices; Topiramate	2016
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. International journal of clinical practice, 2014, Volume: 68, Issue:12 Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2014
Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2014, Volume: 61, Issue:10 Topics: Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Europe; Fructose; Humans; Naltrexone; Obesity; Phentermine; Product Surveillance, Postmarketing; Topiramate; United States; United States Food and Drug Administration	2014
Review of pharmacotherapy options for the management of obesity. Journal of the American Association of Nurse Practitioners, 2016, Volume: 28, Issue:2 Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; United States	2016
Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness. Addiction science & clinical practice, 2016, 09-15, Volume: 11, Issue:1 Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Female; Fructose; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Taurine; Topiramate; United States; United States Department of Veterans Affairs; Veterans; Young Adult	2016
More Treatments on Deck for Alcohol Use Disorder. JAMA, 2017, Jun-13, Volume: 317, Issue:22 Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline	2017
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice? Addiction (Abingdon, England), 2018, Volume: 113, Issue:2 Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate	2018
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2021, 08-03, Volume: 193, Issue:30 Topics: Alcohol Deterrents; Alcoholism; Appetite Depressants; Humans; Naltrexone; Social Support; Topiramate	2021
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder. JAMA network open, 2022, 05-02, Volume: 5, Issue:5 Topics: Alcoholism; Baclofen; Female; Gabapentin; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Naltrexone; Retrospective Studies; Topiramate	2022
Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats. Einstein (Sao Paulo, Brazil), 2022, Volume: 20 Topics: Animals; Bupropion; Humans; Male; Naltrexone; Obesity; Rats; Rats, Wistar; Subcutaneous Fat; Topiramate	2022
Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. Obesity (Silver Spring, Md.), 2023, Volume: 31, Issue:5 Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Health Care Costs; Health Services Accessibility; Liraglutide; Naltrexone; Orlistat; Phentermine; Topiramate	2023